Published in Arterioscler Thromb Vasc Biol on November 11, 2004
Macrophage death and defective inflammation resolution in atherosclerosis. Nat Rev Immunol (2009) 5.03
Liver X receptors as integrators of metabolic and inflammatory signaling. J Clin Invest (2006) 4.92
Molecular regulation of HDL metabolism and function: implications for novel therapies. J Clin Invest (2006) 3.76
The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J Lipid Res (2008) 3.71
Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR. Nat Rev Mol Cell Biol (2012) 2.78
Ligand activation of LXR beta reverses atherosclerosis and cellular cholesterol overload in mice lacking LXR alpha and apoE. J Clin Invest (2007) 2.24
Liver x receptor signaling pathways and atherosclerosis. Arterioscler Thromb Vasc Biol (2010) 1.79
Cholesterol, inflammation and innate immunity. Nat Rev Immunol (2015) 1.72
LXR promotes the maximal egress of monocyte-derived cells from mouse aortic plaques during atherosclerosis regression. J Clin Invest (2010) 1.67
The role of fatty acid binding proteins in metabolic syndrome and atherosclerosis. Curr Opin Lipidol (2005) 1.53
Cytochrome P450 and gene activation--from pharmacology to cholesterol elimination and regression of atherosclerosis. Eur J Clin Pharmacol (2008) 1.52
Future therapeutic directions in reverse cholesterol transport. Curr Atheroscler Rep (2010) 1.46
Liver LXRα expression is crucial for whole body cholesterol homeostasis and reverse cholesterol transport in mice. J Clin Invest (2012) 1.38
The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis? J Lipid Res (2010) 1.36
Liver x receptors in atherosclerosis and inflammation. Circ Res (2011) 1.31
Phenotypic polarization of macrophages in atherosclerosis. Arterioscler Thromb Vasc Biol (2013) 1.29
Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR-/- and apoE-/- mice. J Lipid Res (2009) 1.27
Non-redundant roles for LXRalpha and LXRbeta in atherosclerosis susceptibility in low density lipoprotein receptor knockout mice. J Lipid Res (2010) 1.22
Liver X receptors alpha and beta regulate renin expression in vivo. J Clin Invest (2005) 1.13
Nuclear receptors as drug targets for metabolic disease. Adv Drug Deliv Rev (2010) 1.10
Absence of stearoyl-CoA desaturase-1 ameliorates features of the metabolic syndrome in LDLR-deficient mice. J Lipid Res (2007) 1.09
Sterol regulation of metabolism, homeostasis, and development. Annu Rev Biochem (2011) 1.08
LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse. J Lipid Res (2009) 1.08
Macrophages heterogeneity in atherosclerosis - implications for therapy. J Cell Mol Med (2010) 1.05
Myeloid differentiation primary response protein 88 couples reverse cholesterol transport to inflammation. Cell Metab (2010) 1.01
Nuclear receptors and inflammatory diseases. Exp Biol Med (Maywood) (2008) 1.01
Activation of liver X receptor decreases atherosclerosis in Ldlr⁻/⁻ mice in the absence of ATP-binding cassette transporters A1 and G1 in myeloid cells. Arterioscler Thromb Vasc Biol (2013) 1.01
Phosphorylation of liver X receptor alpha selectively regulates target gene expression in macrophages. Mol Cell Biol (2008) 0.99
Antiatherosclerotic effects of a novel synthetic tissue-selective steroidal liver X receptor agonist in low-density lipoprotein receptor-deficient mice. J Pharmacol Exp Ther (2008) 0.99
Inhibition of ERK1/2 and activation of liver X receptor synergistically induce macrophage ABCA1 expression and cholesterol efflux. J Biol Chem (2009) 0.98
LXR as a novel antithrombotic target. Blood (2011) 0.97
Differential anti-atherosclerotic effects in the innominate artery and aortic sinus by the liver X receptor agonist T0901317. Atherosclerosis (2008) 0.95
Interaction of cowpea mosaic virus nanoparticles with surface vimentin and inflammatory cells in atherosclerotic lesions. Nanomedicine (Lond) (2012) 0.95
Hypercholesterolemia links hematopoiesis with atherosclerosis. Trends Endocrinol Metab (2012) 0.94
Liver X receptor activation promotes macrophage-to-feces reverse cholesterol transport in a dyslipidemic hamster model. J Lipid Res (2009) 0.92
Therapeutic strategies to deplete macrophages in atherosclerotic plaques. Br J Clin Pharmacol (2012) 0.88
LXR agonist increases apoE secretion from HepG2 spheroid, together with an increased production of VLDL and apoE-rich large HDL. Lipids Health Dis (2011) 0.86
Effect of T0901317 on hepatic proinflammatory gene expression in apoE-/- mice fed a high-fat/high-cholesterol diet. Inflammation (2007) 0.85
Differential effects of activation of liver X receptor on plasma lipid homeostasis in wild-type and lipoprotein clearance-deficient mice. Atherosclerosis (2009) 0.84
Nanoparticles containing a liver X receptor agonist inhibit inflammation and atherosclerosis. Adv Healthc Mater (2014) 0.84
Differential regulation of gene expression by LXRs in response to macrophage cholesterol loading. Mol Endocrinol (2013) 0.83
The human myeloperoxidase gene is regulated by LXR and PPARalpha ligands. Biochem Biophys Res Commun (2006) 0.83
The role of a murine transplantation model of atherosclerosis regression in drug discovery. Curr Opin Investig Drugs (2009) 0.82
Low high-density lipoprotein cholesterol: current status and future strategies for management. Vasc Health Risk Manag (2010) 0.82
Liver X receptors at the intersection of lipid metabolism and atherogenesis. Atherosclerosis (2015) 0.81
Regression of atherosclerosis: insights from animal and clinical studies. Ann Glob Health (2013) 0.80
Activation of liver X receptor (LXR) inhibits receptor activator of nuclear factor κB ligand (RANKL)-induced osteoclast differentiation in an LXRβ-dependent mechanism. J Biol Chem (2011) 0.80
The orphan nuclear receptors at their 25-year reunion. J Mol Endocrinol (2013) 0.80
The macrophage LBP gene is an LXR target that promotes macrophage survival and atherosclerosis. J Lipid Res (2014) 0.80
Macrophage-independent regulation of reverse cholesterol transport by liver X receptors. Arterioscler Thromb Vasc Biol (2014) 0.79
Development of therapeutic polymeric nanoparticles for the resolution of inflammation. Adv Healthc Mater (2014) 0.79
Increased inflammation in atherosclerotic lesions of diabetic Akita-LDLr⁻/⁻ mice compared to nondiabetic LDLr⁻/⁻ mice. Exp Diabetes Res (2012) 0.78
Poly(ADP-ribose) Polymerase 1 Represses Liver X Receptor-mediated ABCA1 Expression and Cholesterol Efflux in Macrophages. J Biol Chem (2016) 0.77
Increased Proinflammatory Cytokine Production and Decreased Cholesterol Efflux Due to Downregulation of ABCG1 in Macrophages Exposed to Indoxyl Sulfate. Toxins (Basel) (2015) 0.77
Modulation of Macrophage Gene Expression via Liver X Receptor α Serine 198 Phosphorylation. Mol Cell Biol (2015) 0.77
Stimulation of Liver X Receptor Has Potent Anti-HIV Effects in a Humanized Mouse Model of HIV Infection. J Pharmacol Exp Ther (2015) 0.77
Lesion macrophages are a key target for the antiatherogenic effects of LXR agonists. Arterioscler Thromb Vasc Biol (2005) 0.77
Liver X Receptors Link Lipid Metabolism and Inflammation. FEBS Lett (2017) 0.76
Identification of biological markers of liver X receptor (LXR) activation at the cell surface of human monocytes. PLoS One (2012) 0.76
EEPD1 Is a Novel LXR Target Gene in Macrophages Which Regulates ABCA1 Abundance and Cholesterol Efflux. Arterioscler Thromb Vasc Biol (2017) 0.76
Synthetic LXR agonist suppresses endogenous cholesterol biosynthesis and efficiently lowers plasma cholesterol. Curr Pharm Biotechnol (2011) 0.76
Liver X Receptor: Crosstalk Node for the Signaling of Lipid Metabolism, Carbohydrate Metabolism, and Innate Immunity. Curr Signal Transduct Ther (2008) 0.76
Blood cellular mutant LXR-α protein stability governs initiation of coronary heart disease. World J Cardiol (2013) 0.76
Ligands of Therapeutic Utility for the Liver X Receptors. Molecules (2017) 0.75
Promiscuous activity of the LXR antagonist GSK2033 in a mouse model of fatty liver disease. Biochem Biophys Res Commun (2016) 0.75
E17110 promotes reverse cholesterol transport with liver X receptor β agonist activity in vitro. Acta Pharm Sin B (2016) 0.75
Regulation of macrophage cholesterol efflux and liver X receptor α activation by nicotine. Int J Clin Exp Med (2015) 0.75
Liver X Receptors as Therapeutic Targets for Managing Cholesterol: Implications for Atherosclerosis and Other Inflammatory Conditions. Clin Lipidol (2009) 0.75
Liver X receptors and atherosclerosis: it is not all cholesterol. Arterioscler Thromb Vasc Biol (2014) 0.75
Phosphatidylcholine: Greasing the Cholesterol Transport Machinery. Lipid Insights (2016) 0.75
ATP-binding cassette transporter A1 expression is decreased in preeclamptic placentas. Reprod Sci (2012) 0.75
Erralpha and Gabpa/b specify PGC-1alpha-dependent oxidative phosphorylation gene expression that is altered in diabetic muscle. Proc Natl Acad Sci U S A (2004) 6.53
Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest (2004) 4.65
Molecular determinants of crosstalk between nuclear receptors and toll-like receptors. Cell (2005) 4.30
Redundant pathways for negative feedback regulation of bile acid production. Dev Cell (2002) 3.51
Identification of macrophage liver X receptors as inhibitors of atherosclerosis. Proc Natl Acad Sci U S A (2002) 2.56
ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res (2012) 2.51
Bcl-6 and NF-kappaB cistromes mediate opposing regulation of the innate immune response. Genes Dev (2010) 2.31
Ligand activation of LXR beta reverses atherosclerosis and cellular cholesterol overload in mice lacking LXR alpha and apoE. J Clin Invest (2007) 2.24
Impaired development of atherosclerosis in hyperlipidemic Ldlr-/- and ApoE-/- mice transplanted with Abcg1-/- bone marrow. Arterioscler Thromb Vasc Biol (2006) 2.22
Promoter-specific roles for liver X receptor/corepressor complexes in the regulation of ABCA1 and SREBP1 gene expression. Mol Cell Biol (2003) 2.10
A natural product that lowers cholesterol as an antagonist ligand for FXR. Science (2002) 1.99
Age-accelerated atherosclerosis correlates with failure to upregulate antioxidant genes. Circ Res (2009) 1.88
Psychotropic medication patterns among youth in foster care. Pediatrics (2008) 1.81
PPARdelta-mediated antiinflammatory mechanisms inhibit angiotensin II-accelerated atherosclerosis. Proc Natl Acad Sci U S A (2008) 1.69
Regulation of PPARgamma coactivator 1alpha (PGC-1alpha) signaling by an estrogen-related receptor alpha (ERRalpha) ligand. Proc Natl Acad Sci U S A (2004) 1.60
A soluble receptor decoy protects rats against anthrax lethal toxin challenge. J Infect Dis (2005) 1.54
Smoldering rheumatoid arthritis: is the Canadian healthcare system neglecting a significant disease population? J Rheumatol (2008) 1.46
Liver LXRα expression is crucial for whole body cholesterol homeostasis and reverse cholesterol transport in mice. J Clin Invest (2012) 1.38
Regulation of complement C3 expression by the bile acid receptor FXR. J Biol Chem (2004) 1.35
Anthrax toxin receptor 2-dependent lethal toxin killing in vivo. PLoS Pathog (2006) 1.34
Phenotypic polarization of macrophages in atherosclerosis. Arterioscler Thromb Vasc Biol (2013) 1.29
The Bcl6-SMRT/NCoR cistrome represses inflammation to attenuate atherosclerosis. Cell Metab (2012) 1.24
Non-redundant roles for LXRalpha and LXRbeta in atherosclerosis susceptibility in low density lipoprotein receptor knockout mice. J Lipid Res (2010) 1.22
Denervation of skin in neuropathies: the sequence of axonal and Schwann cell changes in skin biopsies. Brain (2007) 1.21
Identification of the antineoplastic agent 6-mercaptopurine as an activator of the orphan nuclear hormone receptor Nurr1. J Biol Chem (2003) 1.16
Nurr1-RXR heterodimers mediate RXR ligand-induced signaling in neuronal cells. Genes Dev (2003) 1.13
Lymphotoxin-alpha- and lymphotoxin-beta-deficient mice differ in susceptibility to scrapie: evidence against dendritic cell involvement in neuroinvasion. J Virol (2002) 1.13
A nuclear receptor corepressor-dependent pathway mediates suppression of cytokine-induced C-reactive protein gene expression by liver X receptor. Circ Res (2006) 1.12
Small RNA sequencing reveals microRNAs that modulate angiotensin II effects in vascular smooth muscle cells. J Biol Chem (2012) 1.09
Farnesoid X receptor regulates bile acid-amino acid conjugation. J Biol Chem (2003) 1.07
Impaired development of atherosclerosis in Abcg1-/- Apoe-/- mice: identification of specific oxysterols that both accumulate in Abcg1-/- Apoe-/- tissues and induce apoptosis. Arterioscler Thromb Vasc Biol (2010) 1.07
Regulation of cholesterol homeostasis and lipid metabolism in skeletal muscle by liver X receptors. J Biol Chem (2002) 1.04
A viral nanoparticle with dual function as an anthrax antitoxin and vaccine. PLoS Pathog (2007) 1.02
Differential roles of cardiomyocyte and macrophage peroxisome proliferator-activated receptor gamma in cardiac fibrosis. Diabetes (2008) 1.02
Biological characterization of a heterodimer-selective retinoid X receptor modulator: potential benefits for the treatment of type 2 diabetes. Endocrinology (2005) 1.01
Bone marrow NR4A expression is not a dominant factor in the development of atherosclerosis or macrophage polarization in mice. J Lipid Res (2013) 1.00
The flip side: Identifying small molecule regulators of nuclear receptors. Chem Biol (2004) 0.99
Synthesis and SAR of 2-aryl-3-aminomethylquinolines as agonists of the bile acid receptor TGR5. Bioorg Med Chem Lett (2010) 0.98
Interaction of cowpea mosaic virus nanoparticles with surface vimentin and inflammatory cells in atherosclerotic lesions. Nanomedicine (Lond) (2012) 0.95
Orphan nuclear receptor modulators. Curr Top Med Chem (2003) 0.95
Detection of carbohydrates and steroids by cation-enhanced nanostructure-initiator mass spectrometry (NIMS) for biofluid analysis and tissue imaging. Anal Chem (2010) 0.94
LXRα is uniquely required for maximal reverse cholesterol transport and atheroprotection in ApoE-deficient mice. J Lipid Res (2012) 0.92
Efficient neutralization of antibody-resistant forms of anthrax toxin by a soluble receptor decoy inhibitor. Antimicrob Agents Chemother (2008) 0.91
Multivalent display of proteins on viral nanoparticles using molecular recognition and chemical ligation strategies. Biomacromolecules (2011) 0.90
Activation of the retinoid X receptor suppresses appetite in the rat. Endocrinology (2003) 0.89
Prevention and treatment of experimental breast cancer with the combination of a new selective estrogen receptor modulator, arzoxifene, and a new rexinoid, LG 100268. Clin Cancer Res (2002) 0.89
The selective estrogen receptor modulator arzoxifene and the rexinoid LG100268 cooperate to promote transforming growth factor beta-dependent apoptosis in breast cancer. Cancer Res (2004) 0.88
Amiodarone and bepridil inhibit anthrax toxin entry into host cells. Antimicrob Agents Chemother (2007) 0.88
Transcriptional repression of ATP-binding cassette transporter A1 gene in macrophages: a novel atherosclerotic effect of angiotensin II. Circ Res (2005) 0.86
Apoptotic cells trigger a membrane-initiated pathway to increase ABCA1. J Clin Invest (2015) 0.83
FXR, a therapeutic target for bile acid and lipid disorders. Mini Rev Med Chem (2005) 0.83
Differential regulation of gene expression by LXRs in response to macrophage cholesterol loading. Mol Endocrinol (2013) 0.83
In vitro transcriptomic prediction of hepatotoxicity for early drug discovery. J Theor Biol (2011) 0.79
Activation of murine pre-proglucagon-producing neurons reduces food intake and body weight. J Clin Invest (2017) 0.79
Regulation of metabolism by nuclear hormone receptors. Prog Mol Biol Transl Sci (2009) 0.77
HIV neuromuscular disease and mitochondrial function. Mitochondrion (2004) 0.77
Liver X receptors and atherosclerosis: it is not all cholesterol. Arterioscler Thromb Vasc Biol (2014) 0.75
A step ahead: strategies for excellence in critical care nursing practice. Crit Care Nurs Clin North Am (2005) 0.75